Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Fineline Cube Jan 11, 2026
Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Fineline Cube Jan 10, 2026
Company Deals

HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization

Fineline Cube Aug 5, 2022

China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...

Company

Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved

Fineline Cube Aug 5, 2022

Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...

Company Drug

Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review

Fineline Cube Aug 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...

Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Company Drug

Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study

Fineline Cube Aug 4, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...

Company Medical Device

Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...

Company Medical Device

Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...

Company Deals

Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues

Fineline Cube Aug 4, 2022

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...

Company Deals

WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld

Fineline Cube Aug 4, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round

Fineline Cube Aug 4, 2022

Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...

Company Drug

Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China

Fineline Cube Aug 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...

Company Drug Legal / IP

ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO

Fineline Cube Aug 4, 2022

China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...

Company

AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines

Fineline Cube Aug 4, 2022

UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...

Company Drug

Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China

Fineline Cube Aug 3, 2022

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...

Company Drug

Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study

Fineline Cube Aug 3, 2022

Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...

Company Drug

Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment

Fineline Cube Aug 3, 2022

Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...

Company Deals

Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing

Fineline Cube Aug 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...

Company Deals

Taibang Biologic Raises $300M in Post-Privatization Financing Round

Fineline Cube Aug 3, 2022

Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...

Company Deals

Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies

Fineline Cube Aug 3, 2022

Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...

Posts pagination

1 … 581 582 583 … 606

Recent updates

  • Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
  • Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
  • Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
  • Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
  • InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Company Drug

Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.